Vismodegib in basal cell carcinoma: Added benefit not proven
Tuesday, November 19, 2013 - 11:00
in Health & Medicine
No added benefit was found with the use of the drug Vismodegib versus the appropriate comparator therapy in a study focused on basal cell carcinoma.